This technology is a combination therapy that addresses the heterogeneity of Diffuse Midline Glioma (DMG) tumors based on inverting the activity of DMG Master Regulator proteins.
Diffuse Midline Glioma (DMG) is an incurable and universally lethal tumor type that emerges in the central nervous system and predominantly affects young children. DMG is characterized by significant tumor heterogeneity, which confers rapid resistance to therapeutic attempts with single drugs. These challenges hinder the development of targeted therapies, as most strategies fail to address the molecular complexity and cell-state diversity of the tumor. Currently, the only available treatment for DMG is palliative radiation therapy, which is non-specific and provides only short-term efficacy.
The technology describes a combination of anti-cancer therapeutics for targeting Diffuse Midline Glioma (DMG) that addresses tumor heterogeneity based on inverting the activity of DMG Master Regulator (MR) proteins, key proteins that determine cell state in individual tumor cells. This technology harnesses a precision medicine platform for discovering MRs in DMG, which represent pharmacologically accessible targets across DMG cell states. Thus, this approach enables the identification and screening of combinations of actionable drugs across heterogeneous DMG tumors, as well as accurate prediction of the efficacy of drugs capable of inverting MR activity in DMG patients.
This technology has been validated with cultured tumor cells derived from patients and patient cell line-derived DMG mouse models, demonstrating a reduction in tumor volume and significant survival benefit.
Patent Pending
IR CU24228
Licensing Contact: Joan Martinez
